Global Regenerative Medicines Market 2022-2026
Technavio has been monitoring the regenerative medicines market and it is poised to grow by $ 28.67 bn during 2022-2026, accelerating at a CAGR of 14.57% during the forecast period. Our report on the regenerative medicines market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
The report offers an up-to-date analysis of the current global market scenario, the latest trends and drivers, and the overall market environment. The market is driven by the increasing prevalence of chronic diseases, increasing support from the public and private healthcare organizations, and increasing the adoption of stem cell therapy.
The regenerative medicines market analysis includes the technology segment and geographic landscape.
Technavio's regenerative medicines market is segmented as below:
- Cell and tissue-based
- Gene therapy
By Geographical Landscape
- North America
- Rest of World (ROW)
This study identifies the increasing number of clinical trials as one of the prime reasons driving the regenerative medicines market growth during the next few years. Also, emerging technological advances and strategic partnerships and acquisitions will lead to sizable demand in the market.
Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our report on the regenerative medicines market covers the following areas:
- Regenerative medicines market sizing
- Regenerative medicines market forecast
- Regenerative medicines market industry analysis
Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading regenerative medicines market vendors that include AbbVie Inc., Amgen Inc., Baxter International Inc., Becton Dickinson, and Co., Cook Group Inc., F. Hoffmann La Roche Ltd., Gilead Sciences Inc., Integra Lifesciences Corp., Johnson and Johnson, Medtronic Plc, Merck and Co. Inc., Mesoblast Ltd., MiMedx Group Inc., Novartis AG, Nuvasive Inc., Organogenesis Inc., Smith and Nephew plc, Thermo Fisher Scientific Inc., Vericel Corp., and Zimmer Biomet Holdings Inc. Also, the regenerative medicines market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. Technavio's market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.Companies Mentioned
AbbVie Inc., Amgen Inc., Baxter International Inc., Becton Dickinson and Co., Cook Group Inc., F. Hoffmann La Roche Ltd., Gilead Sciences Inc., Integra LifeSciences Corp., Johnson and Johnson, Medtronic Plc, Merck and Co. Inc., Mesoblast Ltd., MiMedx Group Inc., Novartis AG, Nuvasive Inc., Organogenesis Inc., Smith and Nephew plc, Thermo Fisher Scientific Inc., Vericel Corp., Zimmer Biomet Holdings Inc.